GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenerx Biopharmaceuticals Inc (OTCPK:RGRX) » Definitions » GF Value

Regenerx Biopharmaceuticals (Regenerx Biopharmaceuticals) GF Value

: $0.00 (As of Today)
View and export this data going back to 2010. Start your Free Trial

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

  1. Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
  2. GuruFocus adjustment factor based on the company’s past returns and growth.
  3. Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-04-16), Regenerx Biopharmaceuticals's share price is $0.0522. Regenerx Biopharmaceuticals's GF Value is $0.00. Therefore, Regenerx Biopharmaceuticals's Price-to-GF-Value for today is .

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Regenerx Biopharmaceuticals is Not Valued.


Regenerx Biopharmaceuticals  (OTCPK:RGRX) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)Predictable Companies that possibly be Value Traps
Significantly OvervaluedPredictable Companies which are Significantly Overvalued
Modestly OvervaluedPredictable Companies which are Modestly Overvalued
Fairly ValuedPredictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Regenerx Biopharmaceuticals's Price-to-GF-Value for today is calculated as

Price-to-GF-Value=Share Price/GF Value
=0.0522/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regenerx Biopharmaceuticals GF Value Related Terms

Thank you for viewing the detailed overview of Regenerx Biopharmaceuticals's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Regenerx Biopharmaceuticals (Regenerx Biopharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
15245 Shady Grove Road, Suite 470, Rockville, MD, USA, 20850
Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.
Executives
Aptafin S P A other: Member of 10% owner group VIALE SHAKESPEARE 47, ROME L6 00144
Alessandro Noseda director C/O 15245 SHADY GROVE ROAD, SUITE 470, ROCKVILLE MD 20850
S.a. Sinaf 10 percent owner 26 BOULEVARD ROYAL, LUXEMBOURG N4 L-2449
Spa Essetifin 10 percent owner VIA SUDAFRICA 20, ROME L6 00144
Francesca Cavazza 10 percent owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Silvia Cavazza 10 percent owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Enrico Cavazza 10 percent owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Preta Martina Cavazza 10 percent owner VIA SUDAFRICA 20, ROME L6 00144
Mauro Bove director C/O REGENERX BIOPHARMACEUTICALS, INC., 3 BETHESDA METRO CENTER - SUITE 630, BETHESDA MD 20814
R Don Elsey director 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
J J Finkelstein director
Joseph C Mcnay director 3 BETHESDA METRO CENTER STE 700, C/O REGENERX BIOPHARMACEUTICALS INC, BETHESDA MD 20814
Allan L Goldstein director
Dane R Saglio officer: Chief Financial Officer
Aria Digital 10 percent owner 22ND FL, PARKVIEW TOWER,, 248 JUNGJAIL-RO, BUNDANG-GU,, SEONGNAM-SI, GYEONGGI-DO M4 463-863